OTLC Oncotelic Therapeutics, Inc. revenue, earnings and financials
For the quarter ended June 30, 2026, Oncotelic Therapeutics, Inc. reported revenue of $250K, net income of $388K and diluted EPS of $0.00; for the fiscal year ended December 2025 revenue was n/a.
OTLC annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$3.19M, net income $249M (margin n/a), EPS $0.59
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$3.58M, net income −$4.52M (margin n/a), EPS −$0.01
- Fiscal year ended Dec 2023: revenue $70.0K, gross profit n/a, operating income −$6.65M, net income −$7.90M (margin -11290.1%), EPS −$0.02
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$9.72M, net income $5.09M (margin n/a), EPS $0.01
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$9.13M, net income −$9.39M (margin n/a), EPS −$0.03
OTLC quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $250K, net income $388K, EPS $0.00
- Quarter ended Mar 31, 2026: revenue n/a, net income −$2.19M, EPS $0.00
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income $250M, EPS n/a
- Quarter ended Sep 30, 2025: revenue n/a, net income −$1.05M, EPS n/a
- Quarter ended Jun 30, 2025: revenue n/a, net income $278K, EPS $0.00
- Quarter ended Mar 31, 2025: revenue n/a, net income −$299K, EPS $0.00
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$601K, EPS $0.00
- Quarter ended Sep 30, 2024: revenue n/a, net income −$3.30M, EPS −$0.01
- Quarter ended Jun 30, 2024: revenue n/a, net income −$210K, EPS $0.00
- Quarter ended Mar 31, 2024: revenue n/a, net income −$409K, EPS $0.00
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$736K, EPS n/a
- Quarter ended Sep 30, 2023: revenue $70.0K, net income $115K, EPS $0.00
- Quarter ended Jun 30, 2023: revenue n/a, net income −$6.76M, EPS n/a
- Quarter ended Mar 31, 2023: revenue n/a, net income −$525K, EPS $0.00
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$5.29M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$778K, EPS $0.00
- Quarter ended Jun 30, 2022: revenue n/a, net income $16.0M, EPS $0.04
- Quarter ended Mar 31, 2022: revenue n/a, net income −$4.85M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$1.79M, EPS $0.01
- Quarter ended Sep 30, 2021: revenue n/a, net income −$1.56M, EPS $0.00
OTLC cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$1.38M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$740K, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$1.32M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$1.45M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$4.43M, share buybacks n/a
OTLC balance sheet
- Jun 30, 2026: cash n/a, total assets $395M, total liabilities $131M, shareholders' equity $265M
- Mar 31, 2026: cash n/a, total assets $394M, total liabilities $132M, shareholders' equity $263M
- Dec 31, 2025: cash n/a, total assets $393M, total liabilities $131M, shareholders' equity $263M
- Sep 30, 2025: cash $409K, total assets $28.2M, total liabilities $20.1M, shareholders' equity $9.05M
- Jun 30, 2025: cash $88.0K, total assets $26.7M, total liabilities $19.3M, shareholders' equity $8.30M
- Mar 31, 2025: cash $79.2K, total assets $26.7M, total liabilities $19.5M, shareholders' equity $8.02M
- Dec 31, 2024: cash $86.1K, total assets $26.7M, total liabilities $19.2M, shareholders' equity $8.25M
- Sep 30, 2024: cash $149K, total assets $26.8M, total liabilities $18.7M, shareholders' equity $8.85M
Is OTLC profitable?
Yes. Oncotelic Therapeutics, Inc. earned $248M over the last four quarters.